drugset / Trial / NCT05447286
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
RandomizedCrossoverQuadruple-blindOther
Summary
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.
Timeline
- Start
- 2023-05-15
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Oxycodone | Other / unclassified | 15 mg | — |
| Comparator | Oxycodone | Other / unclassified | 30 mg | — |
| Comparator | RISEVISTINEL | Small molecule | 50 mg | — |
| Comparator | RISEVISTINEL | Small molecule | 150 mg | — |